Targeting mGlu7 Receptor using GOLD and Discovery Studio

The metabotropic glutamate 7 (mGlu7) receptor plays a crucial role in synaptic regulation, making it a promising target for therapeutic interventions in conditions such as post-traumatic stress disorder, epilepsy, and anxiety. XAP044 is a negative allosteric modulator of mGlu7 that prevents receptor activation by stabilizing the Venus flytrap domain in an open state. We combined computational modeling with BIOVIA Discovery Studio, docking simulations with GOLD, and mutagenesis experiments, and uncovered a unique mechanism of action of XAP044.

Whether you are a medicinal chemist, computational biologist, or neuroscientist, don’t miss the opportunity to learn how integrating computational and experimental approaches can accelerate breakthroughs in drug discovery.

Webinar highlights:

• Learn how molecular docking with GOLD and BIOVIA Discovery Studio facilitated the identification of a novel inhibitory site on the mGlu7 receptor.
• Gain insights into the synergy of computational and experimental approaches for targeting allosteric sites in drug discovery.
• Discover the power of structure-based drug design in advancing CNS pharmacology.